Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

DDAVP Articles

Watson agrees to buy portfolio of drugs due to be divested on Teva-Barr merger

1 December 2008

Barr's profits up 24% to $76M

15 May 2006

Teva's generic desmopressin cleared in USA

6 February 2006

Ferring's new Copenhagen HQ opened, and future objectives revealed

1 April 2002

FDA Approval News In Brief

2 April 1998

R-PR's 18% EPS Rise Drives Parent Co In 3rd Qtr

4 November 1996

R-PR Posts Profits Climb But Flat Turnover In First Half

5 August 1996

Rhone-Poulenc Rorer Beats 1st-Qtr Forecasts

6 May 1996

R-PR To launch Oral Diabetes Insipidus Drug

19 February 1996

ALKERMES UNVEILS ORALEASE DATA

4 July 1994

DESMOPRESSIN NASAL SPRAY

9 May 1994

RHONE-POULENC RORER '93 RESULTS BELOW EXPECTATIONS

7 February 1994

RHONE-POULENC: A TRANSFORMATION

16 August 1993

ADVANCES BY US DRUG COMPANIES IN 2nd QTR

26 July 1993

RHONE-POULENC RORER SALES $4 BILLION IN 1992

8 February 1993

RHONE-POULENC RORER NET INCOME UP 13.4%

2 November 1992

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS